Literature DB >> 28861419

Direct oral anticoagulants: analysis of worldwide use and popularity using Google Trends.

Giuseppe Lippi1, Camilla Mattiuzzi2, Gianfranco Cervellin3, Emmanuel J Favaloro4.   

Abstract

BACKGROUND: Four direct oral anticoagulants (DOACs) have been approved for clinical use by many medicines regulatory agencies around the world. Due to increasing use of these drugs in routine practice, we planned an original study to investigate their worldwide diffusion using a popular Web-search engine.
METHODS: Two electronic searches were performed using Google Trends, the former using the keywords "warfarin" AND "heparin" AND "fondaparinux", and the latter using the keywords "warfarin" AND "dabigatran" AND "rivaroxaban" AND "apixaban" AND "edoxaban", both using the search criterion "prescription drug". No language restriction was applied, and the searches were carried out from the first date available in Google Trends (January 1st, 2004) to present time (June 1st, 2017).
RESULTS: The median Google Trends score of warfarin (i.e., 86) was consistently higher than that of heparin (54; P<0.001), fondaparinux (6; P<0.001), dabigatran (11; P<0.001), rivaroxaban (5; P<0.001), apixaban (1; P<0.001) and edoxaban (1; P<0.001). Specific analysis of the trends shows that the score of warfarin exhibits a highly significant decrease over time (r=-0.40; P<0.001), whilst that of heparin has remained virtually unchanged (r=0.12; P=0.127), and that of fondaparinux has marginally increased (r=0.16; P=0.038). As regards DOACs, the scores of these drugs significantly increased during the search period (dabigatran, r=0.79; rivaroxaban, r=0.99; apixaban, r=0.98; edoxaban, r=0.78; all P<0.001). When the analysis was limited to the past five years, the dabigatran score significantly decreased (r=-0.57; P<0.001), whereas that of the other DOACs exhibited an even sharper increase. Most Google searches for DOACs were performed in North America, central-eastern Europe and Australia.
CONCLUSIONS: The results of our analysis suggest that the popularity of DOACs is constantly increasing around the world, whereas that of warfarin has exhibited a constant and inexorable decline.

Entities:  

Keywords:  Anticoagulants; Google Trends; direct oral anticoagulants (DOACs); laboratory

Year:  2017        PMID: 28861419      PMCID: PMC5566735          DOI: 10.21037/atm.2017.06.65

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  26 in total

Review 1.  Cardiology patient page. Warfarin versus novel oral anticoagulants: how to choose?

Authors:  Rishi K Wadhera; Cori E Russell; Gregory Piazza
Journal:  Circulation       Date:  2014-11-25       Impact factor: 29.690

2.  Laboratory monitoring of direct oral anticoagulants (DOACs)-The perfect storm?

Authors:  Giuseppe Lippi; Emmanuel J Favaloro
Journal:  Ann Transl Med       Date:  2017-01

3.  Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014.

Authors:  Jeffrey I Weitz; William Semchuk; Alexander G G Turpie; William D Fisher; Cindy Kong; Antonio Ciaccia; John A Cairns
Journal:  Clin Ther       Date:  2015-10-16       Impact factor: 3.393

Review 4.  Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?

Authors:  Giuseppe Lippi; Emmanuel J Favaloro
Journal:  Clin Chem Lab Med       Date:  2015-02       Impact factor: 3.694

5.  Replacing warfarin therapy with the newer direct oral anticoagulants, or simply a growth in anticoagulation therapy? Implications for pathology testing.

Authors:  Emmanuel J Favaloro; Leonardo Pasalic; Giuseppe Lippi
Journal:  Pathology       Date:  2017-08-19       Impact factor: 5.306

6.  Linking Annual Prescription Volume of Antidepressants to Corresponding Web Search Query Data: A Possible Proxy for Medical Prescription Behavior?

Authors:  Maximilian Gahr; Zeljko Uzelac; René Zeiss; Bernhard J Connemann; Dirk Lang; Carlos Schönfeldt-Lecuona
Journal:  J Clin Psychopharmacol       Date:  2015-12       Impact factor: 3.153

7.  National Utilization and Forecasting of Ototopical Antibiotics: Medicaid Data Versus "Dr. Google".

Authors:  Matthew G Crowson; Kristine Schulz; Debara L Tucci
Journal:  Otol Neurotol       Date:  2016-09       Impact factor: 2.311

8.  Current Status and Time Trends of Oral Anticoagulation Use Among Chinese Patients With Nonvalvular Atrial Fibrillation: The Chinese Atrial Fibrillation Registry Study.

Authors:  San-Shuai Chang; Jian-Zeng Dong; Chang-Sheng Ma; Xin Du; Jia-Hui Wu; Ri-Bo Tang; Shi-Jun Xia; Xue-Yuan Guo; Rong-Hui Yu; De-Yong Long; Rong Bai; Nian Liu; Cai-Hua Sang; Chen-Xi Jiang; Xiao-Hui Liu; Jian-Hong Pan; Gregory Y H Lip
Journal:  Stroke       Date:  2016-06-09       Impact factor: 7.914

9.  Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark.

Authors:  Kasper Gadsbøll; Laila Staerk; Emil Loldrup Fosbøl; Caroline Sindet-Pedersen; Anna Gundlund; Gregory Y H Lip; Gunnar Hilmar Gislason; Jonas Bjerring Olesen
Journal:  Eur Heart J       Date:  2017-03-21       Impact factor: 29.983

10.  Is Google Trends a reliable tool for digital epidemiology? Insights from different clinical settings.

Authors:  Gianfranco Cervellin; Ivan Comelli; Giuseppe Lippi
Journal:  J Epidemiol Glob Health       Date:  2017-06-09
View more
  13 in total

1.  Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world.

Authors:  Madan Raj Aryal; Rohit Gosain; Anthony Donato; Han Yu; Anjan Katel; Yashoda Bhandari; Rashmi Dhital; Peter A Kouides
Journal:  Blood Adv       Date:  2019-08-13

2.  Periprocedural Bridging in Patients with Venous Thromboembolism: A Systematic Review.

Authors:  Christine Baumgartner; Ivan de Kouchkovsky; Evans Whitaker; Margaret C Fang
Journal:  Am J Med       Date:  2019-01-16       Impact factor: 4.965

3.  Treatment and Outcomes of Acute Pulmonary Embolism and Deep Venous Thrombosis: The CVRN VTE Study.

Authors:  Margaret C Fang; Dongjie Fan; Sue Hee Sung; Daniel M Witt; John R Schmelzer; Marc S Williams; Steven H Yale; Christine Baumgartner; Alan S Go
Journal:  Am J Med       Date:  2019-06-25       Impact factor: 4.965

4.  Prescribing Trends of Oral Anticoagulants from 2010 to 2020 in Shanghai, China: A Retrospective Study.

Authors:  Chi Zhang; Jia Wang; Ya Yang; Er-Li Ma; Hou-Wen Lin; Bing-Long Liu; Zhi-Chun Gu
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

Review 5.  A review of guidelines on anticoagulation reversal across different clinical scenarios - Is there a general consensus?

Authors:  Truman J Milling; Charles V Pollack
Journal:  Am J Emerg Med       Date:  2020-05-28       Impact factor: 4.093

6.  Web search popularity, publicity, and utilization of direct oral anticoagulants in the United States, 2008-2018: A STROBE-compliant study.

Authors:  Panayiotis D Ziakas; Eleftherios Mylonakis
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.889

7.  A New Test for the Detection of Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in the Emergency Room Setting.

Authors:  Galit H Frydman; Felix Ellett; Elizabeth M Van Cott; Douglas Hayden; Maulik Majmudar; Charles R Vanderburg; Haley Dalzell; Divya L Padmanabhan; Nick Davis; Julianne Jorgensen; Mehmet Toner; James G Fox; Ronald G Tompkins
Journal:  Crit Care Explor       Date:  2019-08-20

8.  Influence of Antiplatelet and Anticoagulant Drug Use on Outcomes after Chronic Subdural Hematoma Drainage.

Authors:  Michael T C Poon; Catherine Rea; Angelos G Kolias; Paul M Brennan
Journal:  J Neurotrauma       Date:  2019-02-01       Impact factor: 5.269

9.  Worldwide antipsychotic drug search intensities: pharmacoepidemological estimations based on Google Trends data.

Authors:  Richard Ågren
Journal:  Sci Rep       Date:  2021-06-23       Impact factor: 4.379

10.  Non-bleeding Adverse Events with the Use of Direct Oral Anticoagulants: A Sequence Symmetry Analysis.

Authors:  Géric Maura; Cécile Billionnet; Joël Coste; Alain Weill; Anke Neumann; Antoine Pariente
Journal:  Drug Saf       Date:  2018-09       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.